Comparative Analysis of Melanotan I and Melanotan II

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Structural Characteristics

Melanotan I

• Amino acid sequence: SYSXEHFRWGKPV 
• Molecular weight: 1646.8 g/mol 
• Molecular formula: C78H111N21O19 
• Common names: Afamelanotide, SCENESSE 

Melanotan II

• Amino acid sequence: Nle-DHRFWK 
• Molecular weight: 1024.2 g/mol 
• Molecular formula: C50H69N15O9 
• Common names: Bremelanotide (modified analogue) 

Although both are derivatives of alpha-melanocyte stimulating hormone (α-MSH), their molecular structures diverge significantly. Melanotan I retains a closer resemblance to the parent hormone, while Melanotan II demonstrates more substantial modifications. These differences contribute to variations in receptor affinity and functional outcomes.

Pharmacological Profile

A comparative overview highlights overlapping as well as distinct physiological effects:

Melanotan I

• Induces pigmentation 
• Modulates lipid metabolism 
• Enhances certain aspects of cognition 
• Influences blood pressure regulation 
• Supports vascular function 
• Investigated in neuroinflammatory disorders 

Melanotan II

• Modulates sexual function, including erectile response 
• Promotes pigmentation 
• Regulates appetite and satiety 
• Influences behavioral control and addictive tendencies 
• Studied in autism spectrum-related behaviors 

Both compounds act on melanocortin receptors but demonstrate nuanced activity that reflects differences in receptor binding patterns.

Receptor Interactions

Melanotan I and II both target melanocortin receptors (MC1R, MC3R, MC4R, MC5R) with minimal activity at MC2R.

• Melanotan I exhibits stronger binding at MC1R, accounting for its pronounced effects on pigmentation. It also interacts with MC5R, expressed in pancreatic islet cells, where activation has been associated with lipid metabolism and potential weight regulation. 
• Melanotan II shows greater affinity for MC4R, which mediates sexual arousal and erectile function. It also engages MC3R, a receptor hypothesized to influence social behavior and repetitive activity patterns, with early research suggesting potential relevance in autism-related symptoms. 

Research and Development Pathways

The clinical development trajectories of the two compounds have diverged substantially:

• Melanotan I was initially explored as a tanning agent. Though interest diminished for several years, it later gained traction as a therapeutic for photosensitivity disorders. Under the name afamelanotide, it is now approved in multiple regions for erythropoietic protoporphyria and continues to be investigated for additional dermatological and neurological conditions. 
• Melanotan II was pursued for sexual dysfunction, including hypoactive sexual desire disorder and erectile dysfunction. A derivative, bremelanotide, emerged as a result of structural modification. Development was complicated by patent disputes and clinical challenges, though it reinforced the compound’s potential therapeutic value in sexual health. 

Clinical Implications

The distinct binding profiles and resulting pharmacodynamics indicate that:

• Melanotan I is more clinically relevant for pigmentation disorders, photoprotection, and metabolic regulation. 
• Melanotan II demonstrates greater promise in sexual medicine and behavioral research, with additional interest in appetite and impulse regulation. 

Conclusion

While Melanotan I and II originate from the same hormonal framework, their structural modifications yield unique clinical applications. The differences in receptor selectivity illustrate how subtle molecular adjustments can reshape pharmacological outcomes. Rather than a question of superiority, the distinction lies in therapeutic suitability for specific indications. Ongoing studies continue to expand understanding of their roles in dermatology, endocrinology, and neurobehavioral research.

REFERENCES

1. Møller, C. L., Raun, K., Jacobsen, M. L., Pedersen, T. Å., Holst, B., Conde-Frieboes, K. W., & Wulff, B. S. (2011). Characterization of murine melanocortin receptors mediating adipocyte lipolysis and examination of signalling pathways involved. Molecular and cellular endocrinology, 341(1-2), 9–17. https://doi.org/10.1016/j.mce.2011.03.010
2. Minakova, E., Lang, J., Medel-Matus, J. S., Gould, G. G., Reynolds, A., Shin, D., Mazarati, A., & Sankar, R. (2019). Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PloS one, 14(1), e0210389. https://doi.org/10.1371/journal.pone.0210389
3. Dorr, R. T., Ertl, G., Levine, N., Brooks, C., Bangert, J. L., Powell, M. B., Humphrey, S., & Alberts, D. S. (2004). Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of dermatology, 140(7), 827–835. https://doi.org/10.1001/archderm.140.7.827

  Product available for research use only: